StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics cash

Cash and short-term investments held at the end of each period.

Outlook Therapeutics's cash was $11.24M at Jun 30, 2026. For fiscal 2025 it was $8.08M, down 45.9% from the year before. Over ten years it grew -1.1% a year on average. The highest annual figure on record is $23.39M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Sep 30, 2025$8.08M-45.9%
FY2024Sep 30, 2024$14.93M-36.2%
FY2023Sep 30, 2023$23.39M+34.5%
FY2022Sep 30, 2022$17.40M+20.2%
FY2021Sep 30, 2021$14.48M+15.5%
FY2020Sep 30, 2020$12.54M+56.4%
FY2019Sep 30, 2019$8.02M+366.7%
FY2018Sep 30, 2018$1.72M-46.1%
FY2017Sep 30, 2017$3.19M+35.4%
FY2016Sep 30, 2016$2.35M-74.1%
FY2015Sep 30, 2015$9.07M+286.1%
FY2014Sep 30, 2014$2.35M–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$11.24M+26.3%
Q2 FY2026CQ1 2026Mar 31, 2026$7.75M+2.5%
Q1 FY2026CQ4 2025Dec 31, 2025$8.68M+52.2%
Q4 FY2025CQ3 2025Sep 30, 2025$8.08M-45.9%
Q3 FY2025CQ2 2025Jun 30, 2025$8.90M-72.2%
Q2 FY2025CQ1 2025Mar 31, 2025$7.56M-84.0%
Q1 FY2025CQ4 2024Dec 31, 2024$5.70M-44.9%
Q4 FY2024CQ3 2024Sep 30, 2024$14.93M-36.2%
Q3 FY2024CQ2 2024Jun 30, 2024$32.02M-5.0%
Q2 FY2024CQ1 2024Mar 31, 2024$47.23M+8.3%
Q1 FY2024CQ4 2023Dec 31, 2023$10.36M-80.2%
Q4 FY2023CQ3 2023Sep 30, 2023$23.39M+34.5%
Q3 FY2023CQ2 2023Jun 30, 2023$33.71M+29.5%
Q2 FY2023CQ1 2023Mar 31, 2023$43.63M-37.8%
Q1 FY2023CQ4 2022Dec 31, 2022$52.34M+261.5%
Q4 FY2022CQ3 2022Sep 30, 2022$17.40M-11.7%
Q3 FY2022CQ2 2022Jun 30, 2022$26.02M+367.3%
Q1 FY2022CQ4 2021Dec 31, 2021$70.15M+459.6%
Q4 FY2021CQ3 2021Sep 30, 2021$14.48M-39.6%
Q3 FY2021CQ2 2021Jun 30, 2021$19.69M+323.2%
Q1 FY2021CQ4 2020Dec 31, 2020$5.57M+317.6%
Q4 FY2020CQ3 2020Sep 30, 2020$12.54M+56.4%
Q3 FY2020CQ2 2020Jun 30, 2020$23.95M+70.8%
Q2 FY2020CQ1 2020Mar 31, 2020$4.65M+2892.8%
Q1 FY2020CQ4 2019Dec 31, 2019$1.33M+485.6%
Q4 FY2019CQ3 2019Sep 30, 2019$8.02M+366.7%
Q3 FY2019CQ2 2019Jun 30, 2019$14.03M+18.9%
Q2 FY2019CQ1 2019Mar 31, 2019$155.47K-97.4%
Q1 FY2019CQ4 2018Dec 31, 2018$227.72K-98.4%
Q4 FY2018CQ3 2018Sep 30, 2018$1.72M-46.1%
Q3 FY2018CQ2 2018Jun 30, 2018$11.80M+8332.3%
Q2 FY2018CQ1 2018Mar 31, 2018$5.94M+7224.1%
Q1 FY2018CQ4 2017Dec 31, 2017$13.84M+565.7%
Q4 FY2017CQ3 2017Sep 30, 2017$3.19M+35.4%
Q3 FY2017CQ2 2017Jun 30, 2017$139.90K-99.0%
Q2 FY2017CQ1 2017Mar 31, 2017$81.05K-97.1%
Q1 FY2017CQ4 2016Dec 31, 2016$2.08M–
Q4 FY2016CQ3 2016Sep 30, 2016$2.35M–
Q3 FY2016CQ2 2016Jun 30, 2016$13.56M–
Q2 FY2016CQ1 2016Mar 31, 2016$2.84M–

More Outlook Therapeutics figures

See a number that looks wrong?